Overview

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The primary goal of this pilot study is to investigate whether psilocybin alters neuroplasticity in people with major depressive disorder. The primary hypothesis is that psilocybin will result in neuroplastic changes that parallel improvement in symptoms of depression.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
Heffter Research Institute
Treatments:
Psilocybin